SCHEMBL18174592

SCHEMBL18174592

Cc1ccnc(-c2ccc(-c3c4ccccc4c(-c4ccc(-c5cc(C)ccn5)cc4)c4cc(-c5cccc(-c6ccccc6)c5)ccc34)cc2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.46
CCR1 P32246 1/20 0.42
CCR5 P51681 1/20 0.42
CCR8 P51685 1/20 0.42
MAP4K4 O95819 2/20 0.40
TGFBR1 P36897 2/20 0.40
ASIC3 Q9UHC3 1/20 0.40
ABL1 P00519 4/20 0.39
BCR P11274 4/20 0.39
KDR P35968 1/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38
GLA P06280 1/20 0.38
MAPT P10636 1/20 0.38
ROCK1 Q13464 1/20 0.37
CNR1 P21554 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18174674 0.97 CYP2A6 (0.46) CYP2A6CCR1CCR5CCR8MAP4K4
SCHEMBL15977629 0.97 CYP2A6 (0.48) CYP2A6CCR1CCR5CCR8MAP4K4
SCHEMBL15160984 0.97 CYP2A6 (0.48) CYP2A6CCR1CCR5CCR8MAP4K4
SCHEMBL18174580 0.95 CYP2A6 (0.46) CYP2A6CCR1CCR5CCR8MAP4K4
SCHEMBL10300894 0.92 CYP2A6 (0.50) CYP2A6CCR1CCR5CCR8MAP4K4
SCHEMBL18174555 0.87 CCR1 (0.55) CYP2A6CCR1CCR5CCR8TGFBR1
SCHEMBL10032684 0.86 CYP2A6 (0.46) CYP2A6CCR1CCR5CCR8ASIC3
SCHEMBL10300923 0.86 ASIC3 (0.46) MAP4K4TGFBR1ASIC3PIK3CA
SCHEMBL15977471 0.86 ASIC3 (0.46) MAP4K4TGFBR1ASIC3PIK3CA
SCHEMBL18174595 0.85 CYP2A6 (0.41) CYP2A6CCR1CCR5CCR8ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9478750-B2 Anthracene derivative and organic electroluminescent element using the same JNC CORPORATION (JP) 2016-10-25 US disclosed
US-9478750-B2 Anthracene derivative and organic electroluminescent element using the same JNC CORPORATION (JP) 2016-10-25 US disclosed
US-20150203469-A1 ISOTOPOLOGUES OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL) PIPERIDINE-2-6-DIONE AND METHODS OF PREPARATION THEREOF CELGENE CORPORATION 2015-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150203469-A1 ISOTOPOLOGUES OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL) PIPERIDINE-2-6-DIONE AND METHODS OF PREPARATION THEREOF AQP3, CYP2D6, CYP3A5 CYP2A6 79/4885CCR1 1606/4885CCR5 383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.